AVXL Insider Trading

Insider Ownership Percentage: 11.00%
Insider Buying (Last 12 Months): $32,919.40
Insider Selling (Last 12 Months): $0.00

Anavex Life Sciences Insider Trading History Chart

This chart shows the insider buying and selling history at Anavex Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2M-$1M$0$1M$2MTotal Insider BuyingTotal Insider Selling

Anavex Life Sciences Share Price & Price History

Current Price: $8.30
Price Change: Price Decrease of -0.26 (-3.04%)
As of 04/3/2025 05:00 PM ET

This chart shows the closing price history over time for AVXL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$8.30Closing price on 04/03/25:

Anavex Life Sciences Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Anavex Life Sciences (NASDAQ:AVXL)

31.55% of Anavex Life Sciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at AVXL by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$28Mbought$4.64MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M$0$20MTotal InflowsTotal Outflows
Anavex Life Sciences logo
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Read More on Anavex Life Sciences

Today's Range

Now: $8.30
Low: $7.83
High: $8.40

50 Day Range

MA: $8.89
Low: $7.85
High: $10.49

52 Week Range

Now: $8.30
Low: $3.25
High: $14.44

Volume

1,153,402 shs

Average Volume

1,247,813 shs

Market Capitalization

$706.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Who are the company insiders with the largest holdings of Anavex Life Sciences?

Anavex Life Sciences' top insider shareholders include:
  1. Christopher U Missling (CEO)
  2. Peter DO Donhauser (Director)
  3. Steffen Thomas (Director)
Learn More about top insider investors at Anavex Life Sciences.